Literature DB >> 9124845

Comparative serum bactericidal activities of ceftizoxime and cefotaxime against intermediately penicillin-resistant Streptococcus pneumoniae.

K B Patel1, D P Nicolau, C H Nightingale, R Quintiliani.   

Abstract

In a randomized crossover study involving 12 healthy volunteers, 1 g of ceftizoxime or cefotaxime was administered intravenously every 12 h for a total of three doses on two separate weekends. The duration of serum bactericidal titers (SBTs) greater than 1:2 and the time serum drug concentrations remained above the MIC (T > MIC) were determined against three clinical isolates of Streptococcus pneumoniae with intermediate resistance to penicillin. The duration of SBTs and T > MIC for both antimicrobial agents exceeded 50% of the dosing interval for all isolates. Ceftizoxime's T > MIC was statistically greater than that of cefotaxime, indicating that its longer half-life in serum (1.7 h) compared with that of cefotaxime (approximately 1 h) compensates for its slightly lower microbiologic activity against the penicillin-resistant pneumococci tested in this study.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9124845      PMCID: PMC163626     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Drug-resistant pneumococcal infections in the United States. A problem for clinicians, laboratories, and public health.

Authors:  M S Simberkoff
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

2.  Diminished activity of ceftizoxime in comparison to cefotaxime and ceftriaxone against Streptococcus pneumoniae.

Authors:  D W Haas; C W Stratton; J P Griffin; L Weeks; S C Alls
Journal:  Clin Infect Dis       Date:  1995-03       Impact factor: 9.079

3.  Comparative study of pharmacokinetics and serum bactericidal activity of ceftizoxime and cefotaxime.

Authors:  F Vallée; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

4.  Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin.

Authors:  J D Knudsen; N Frimodt-Møller; F Espersen
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

5.  In vitro killing of penicillin-susceptible, -intermediate, and -resistant strains of Streptococcus pneumoniae by cefotaxime, ceftriaxone, and ceftizoxime: a comparison of bactericidal and inhibitory activity with achievable CSF levels.

Authors:  C W Stratton; K E Aldridge; M S Gelfand
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

Review 6.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

Review 7.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

  7 in total
  1 in total

1.  Bactericidal activities of ceftizoxime and cefotaxime against Streptococcus pneumoniae.

Authors:  K B Waites; T Rivers
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.